Status:

Do Not Prescribe (DNP)

Decision Date:

September 2022

Comments

DNP: NICE TA812 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NHSE commissioned. 

Do Not Prescribe (DNP) Drug Classifications

• 2: Have a lack of data on safety compared with standard therapy
• 4: Have a lack of data on cost-effectiveness compared with standard therapy

search again